Home/Pipeline/Acute Stroke Program

Acute Stroke Program

Acute Ischemic Stroke

ClinicalActive

Key Facts

Indication

Acute Ischemic Stroke

Phase

Clinical

Status

Active

Company

Shionogi

About Shionogi

Shionogi Inc. is a global pharmaceutical company with over 140 years of experience in drug discovery and development, headquartered in Japan with significant US operations. The company specializes in addressing unmet medical needs through innovative treatments for infectious diseases, antivirals, and complex therapeutic areas. Shionogi has built strategic partnerships with industry, government agencies, and biotech companies to advance science with urgency, particularly in response to global health challenges like antimicrobial resistance and COVID-19. The company operates as a publicly traded entity with a strong commitment to ethical business practices and transparent operations.

View full company profile

Therapeutic Areas

Infectious Diseases Antivirals HIV/AIDS Influenza COVID-19 Fragile X Syndrome Acute Ischemic Stroke Metabolic Disorders Oncology Antibiotics

Other Acute Ischemic Stroke Drugs

Drug	Company	Phase	Status
AST-004	Astrocyte Pharmaceuticals	Phase 1/2	IND cleared March 2024